Bellofatto, Marta
Gentile, Luca
Bertini, Alessandro
Tramacere, Irene
Manganelli, Fiore
Fabrizi, Gian Maria
Schenone, Angelo
Santoro, Lucio
Cavallaro, Tiziana
Grandis, Marina
Previtali, Stefano C.
Scarlato, Marina
Allegri, Isabella
Padua, Luca
Pazzaglia, Costanza
Villani, Flavio
Cavalca, Eleonora
Saveri, Paola
Quattrone, Aldo
Valentino, Paola
Tozza, Stefano
Russo, Massimo
Mazzeo, Anna
Vita, Giuseppe
Piacentini, Sylvie
Didato, Giuseppe
Pisciotta, Chiara
Pareyson, Davide http://orcid.org/0000-0001-6854-765X
,
Schirinzi, Giulia
Montesano, Maria
Nuzzo, Sara
Oggiano, Francesca
Calabrese, Daniela
Gemelli, Chiara
Falzone, Yuri
Spina, Emanuele
Longo, Maria
Occhipinti, Giuseppe
Iabichella, Giacomo
Barone, Stefania
Funding for this research was provided by:
Fondazione Telethon (GUP13006)
Article History
Received: 21 April 2023
Revised: 5 July 2023
Accepted: 28 July 2023
First Online: 4 August 2023
Change Date: 21 September 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00415-023-11989-4
Declarations
:
: GMF acknowledges donations from Pfizer to support research activities of his Research Unit, financial support from Akcea, Kedrion, Pfizer for participation in national and international meetings and from Akcea, Alnylam and Pharnext for participation in Advisory Boards; MG acknowledges donations from Sanofi Genzyme to support research activities of her Research Unit, financial support from Alnylam and Sanofi Genzyme for participation in national and international Meetings, participation in Advisory Board of Pfizer, speaker honorarium from Sanofi Genzyme; AM acknowledges financial support from Pfizer, Alnylam and Akcea for participation in national and international meetings, participation in Advisory Board of Pfizer, Alnylam and Akcea; GV acknowledges donations from Pfizer and PTC to support research activities and participation in Advisory Board of Pfizer, Alnylam, Akcea and Pharnext; DP acknowledges donations from Pfizer, LAM Therapeutics and Acceleron to support research activities of his Research Unit, financial support from Pfizer, Alnylam and Kedrion for participation in national and international meetings, participation in Advisory Board of Inflectis, Alnylam, Akcea, Arvinas, Augustine Tx, DTx, speaker honorarium from Alnylam. MB, AB, IT, FM. AS, LS, TC, SCP, MS, IA, LP, CP. DC, PS, AQ, PV, ST, LG, MR, AM, SP, GDD, CP report no disclosure.